Dysautonomia and Non-Motor Complications in PD — MDS 2026

Dysautonomia and Non-Motor Complications in Parkinson's Disease — MDS 2026

The MDS 2026 Congress features extensive programming on autonomic dysfunction and non-motor complications in Parkinson's disease, reflecting the growing recognition that these symptoms significantly impact quality of life and often precede motor signs by years or decades.

Autonomic Dysfunction in PD

Dysautonomia and Non-Motor Complications in Parkinson's Disease — MDS 2026

The MDS 2026 Congress features extensive programming on autonomic dysfunction and non-motor complications in Parkinson's disease, reflecting the growing recognition that these symptoms significantly impact quality of life and often precede motor signs by years or decades.

Autonomic Dysfunction in PD

Cardiovascular Dysregulation

Orthostatic Hypotension

| Feature | Details |
|---------|---------|
| Definition | ≥20 mmHg systolic or ≥10 mmHg diastolic drop within 3 minutes of standing |
| Prevalence | 30-50% of PD patients |
| Pathogenesis | Central autonomic network degeneration, norepinephrine deficiency |
| Symptoms | Lightheadedness, syncope, falls, postprandial worsening |
| Management | Volume expansion, compression garments, midodrine, droxidopa |

MDS 2026 Key Insights:

• OH may be the presenting symptom in up to 10% of PD patients
• Supine hypertension complicates management in 50% of OH patients
• Baroreflex failure precedes cardiac sympathetic denervation
• Non-dopaminergic medications (midodrine, droxidopa) preferred to avoid motor worsening

Supine Hypertension

• Present in 50% of PD patients with OH
• Contribute to nocturnal supine renal sodium loss
• Management: bedtime clonidine, bedtime losartan, elevate head of bed

Heart Rate Variability

• Reduced HRV predicts faster disease progression
• Cardiac sympathetic denervation measured via 123I-MIBG scintigraphy
• Correlates with Braak stage 1-2 (enteric/medullary involvement)

Gastrointestinal Dysfunction

Constipation

| Aspect | Details |
|--------|---------|
| Prevalence | 60-80% |
| Rome Criteria | <3 bowel movements/week, straining, incomplete evacuation |
| Pathogenesis | [Alpha-synuclein](/proteins/alpha-synuclein) deposition in ENS, Lewy bodies in myenteric plexus |
| Colon transit time | Delayed by 2-3x normal |
| Treatment | Fiber, osmotic laxatives, prokinetics, lubiprostone |

Braak Hypothesis Connection:

• Enteric nervous system (ENS) is among the earliest sites of α-syn pathology
• α-Synuclein in submucosal and myenteric neurons precedes CNS involvement
• GI dysfunction may provide biomarkers for prodromal PD detection

Gastroparesis

• Delayed gastric emptying in 30-50%
• Contributes to levodopa malabsorption ("delayed-on" phenomenon)
• Management: domperidone, erythromycin, dietary modifications

Sialorrhea (Excessive Drooling)

• Affects 30-50% of PD patients
• Due to reduced swallow frequency, not increased production
• Treatment: anticholinergics, botulinum toxin to salivary glands

Urinary Dysfunction

Urinary dysfunction occurs in 45-70% of PD patients, primarily as detrusor overactivity[@urinary2024]:

| Type | Prevalence | Mechanism |
|------|------------|------------|
| Urgency/Frequency | 45-70% | Detrusor overactivity from basal ganglia inhibition loss |
| Nocturia | 60-80% | Combination of OH, sleep fragmentation, detrusor overactivity |
| Incomplete emptying | 20-30% | Urethral sphincter bradykinesia |

Management:

• Anticholinergics: solifenacin, tolterodine (watch cognitive side effects)
• Beta-3 agonists: mirabegron
• Intermittent catheterization for retention

Sexual Dysfunction

• Erectile dysfunction: 50-70% of male PD patients
• Reduced libido: 40-60%
• Contributors: autonomic dysfunction, depression, medication effects

Sudomotor Dysfunction

• Anhidrosis or hyperhidrosis in 30-50%
• May present as patchy sweating patterns
• Correlates with disease severity

Sleep Disorders in PD

REM Sleep Behavior Disorder

RBD affects 50-60% of PD patients and is a strong predictor of synucleinopathy[@rbd2025]:

| Feature | Details |
|---------|---------|
| Prevalence | 50-60% in established PD |
| Core criteria | REM sleep without atonia, dream enactment behaviors |
| Polysomnography | REM sleep without atonia + ≥5/80% tonic chin EMG activity |
| Disease association | 80-90% develop parkinsonism or dementia within 10-15 years |

Pathophysiology:

• Subcoeruleus nucleus degeneration (PPTg, SLD)
• Loss of glycinergic/GABAergic inhibition of motor neurons
• Earlier onset RBD predicts more aggressive α-syn pathology

• Clonazepam: 0.25-1.0 mg HS (most effective)
• Melatonin: 3-12 mg HS (better tolerated)
• Bed safety measures

Insomnia

• Prevalence: 60-90%
• Causes: nocturnal akinesia, depression, medication effects, RBD
• Management: sleep hygiene, timed levodopa dosing, cognitive behavioral therapy

Excessive Daytime Sleepiness

• Prevalence: 30-50%
• Evaluation: Epworth Sleepiness Scale, MSLT
• Contributors: medications (dopaminergics, antidepressants), nocturnal sleep disruption

Restless Legs Syndrome

• Prevalence: 15-20% (vs 5-10% in general population)
• Improvement with dopaminergic therapy
• Differential diagnosis from akathisia

Neuropsychiatric Complications

Depression

Depression affects up to 50% of PD patients and is the most common neuropsychiatric symptom[@depression2024]:

| Feature | Details |
|---------|---------|
| Prevalence | 30-50% |
| Timing | Can precede motor symptoms by years |
| Presentation | Anhedonia, guilt, apathy vs somatic symptoms |
| Treatment | SSRIs (citalopram, sertraline), SNRIs, CBT |

MDS 2026 Updates:

• Depression correlates with dorsal raphe and locus coeruleus pathology
• Neurochemical basis: serotonin and norepinephrine depletion
• Tricyclic antidepressants may worsen OH

Anxiety

• Prevalence: 25-40%
• Often co-occurs with depression
• Can manifest as panic attacks, generalized anxiety, or social phobia
• Related to "off" periods and motor fluctuations

Psychosis

Parkinson disease psychosis (PDP) affects 20-40% of patients[@pd psychosis2025]:

| Feature | Details |
|---------|---------|
| Prevalence | 20-40% (all parkinsonism), 50-60% (PDD) |
| Core symptoms | Visual hallucinations, delusions, misidentifications |
| Risk factors | Age, disease duration, cognitive impairment, dopaminergic meds |
| Pathology | Lewy body pathology in ventral temporal cortex, limbic system |

Management Approach:

Apathy

• Prevalence: 30-50%
• Distinct from depression (anhedonia key differential)
• Associated with frontal lobe dysfunction
• Treatment: dopaminergic stimulation, behavioral interventions

Impulse Control Disorders

ICD affects 10-15% of PD patients on dopaminergic therapy[@impulse2024]:

| Disorder | Features |
|----------|----------|
| Pathological gambling | Risk-taking behaviors, financial losses |
| Compulsive shopping | Excessive, unplanned purchases |
| Binge eating | Weight gain, metabolic complications |
| Hypersexuality | Inappropriate sexual behaviors |

Risk Factors:

• Dopamine agonist use (pramipexole, ropinirole > rotigotine)
• Male sex
• Young onset
• Personal/family history of OCD or addiction

• Reduce or discontinue dopamine agonists
• Consider naltrexone (off-label)
• Behavioral therapy

Hallucinations

• Visual hallucinations most common (80-90% of psychotic episodes)
• Often insight-preserved ("les hallucinations")
• Typically begin with minor hallucinations (passage, presence)
• Progress to fully formed visual hallucinations

Cognitive Impairment

Mild Cognitive Impairment in PD

• Prevalence: 20-50%
• Types: executive, attention, memory, visuospatial
• Progression: 50-80% develop dementia over disease course
• Biomarkers: reduced CSF Aβ42, elevated tau, cortical Lewy bodies

Parkinson's Disease Dementia

| Feature | Details |
|---------|---------|
| Prevalence | 30-80% (duration-dependent) |
| Diagnostic criteria | 1 year rule (PDD vs DLB) |
| Core symptoms | Executive dysfunction, attentional fluctuations, visual hallucinations |
| Progression | Median 4-5 years from PDD onset to nursing home |

Treatment:

• Cholinesterase inhibitors: rivastigmine (FDA-approved), donepezil
• Memantine: modest benefits
• Avoid anticholinergics, benzodiazepines

Fatigue

Fatigue affects 40-70% of PD patients and is among the most disabling non-motor symptoms[@fatigue2025]:

| Aspect | Details |
|--------|---------|
| Prevalence | 40-70% |
| Types | Physical, mental, psychological |
| Relationship | Correlates with depression, sleep disorders, disease severity |
| Treatment | Exercise, sleep optimization, modafinil (off-label), caffeine |

Pain

Pain affects 40-60% of PD patients:

| Type | Description |
|------|-------------|
| Musculoskeletal | Rigidity, stiffness, arthritic pain |
| Radicular | Nerve root compression |
| Dystonic | OFF-period cramping, foot dystonia |
| Central | Burning, dysesthetic pain |
| Akathitic | Restless discomfort |

Assessment Tools

Non-Motor Symptoms Scale (NMSS)

• 30 items across 9 domains
• Validated in PD populations
• Used in clinical trials

Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)

• Comprehensive assessment of non-motor symptoms
• Excellent psychometric properties

SCOPA-AUT

• 25 items covering autonomic domains
• Validated for PD

PDSS-2 (Parkinson's Disease Sleep Scale-2)

• 15 items assessing sleep quality

Management Principles

Cross-Links

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Autonomic Nervous System](/entities/autonomic-nervous-system)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [REM Sleep Behavior Disorder](/mechanisms/rbd-neurodegeneration)
• [Parkinson's Disease Dementia](/diseases/parkinsons-disease-dementia)
• [Gut-Brain Axis](/mechanisms/gut-brain-axis)
• [Central Autonomic Network](/circuits/central-autonomic-network)
• [Non-Motor Symptoms in PD — MDS 2026](/events/mds-2026/parkinsons-non-motor-symptoms)

References